These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37977350)

  • 1. Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase.
    Nagaoka K; Bai X; Liu D; Cao K; Mulla J; Ji C; Chen H; Nisar MA; Bay A; Mueller W; Hildebrand G; Gao JS; Lu S; Setoyama H; Tanaka Y; Wands JR; Huang CK
    Cancer Lett; 2024 Jan; 580():216493. PubMed ID: 37977350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
    Huang CK; Iwagami Y; Zou J; Casulli S; Lu S; Nagaoka K; Ji C; Ogawa K; Cao KY; Gao JS; Carlson RI; Wands JR
    Cancer Lett; 2018 Aug; 429():1-10. PubMed ID: 29733964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.
    Huang CK; Iwagami Y; Aihara A; Chung W; de la Monte S; Thomas JM; Olsen M; Carlson R; Yu T; Dong X; Wands J
    PLoS One; 2016; 11(3):e0150336. PubMed ID: 26954680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
    Nagaoka K; Ogawa K; Ji C; Cao KY; Bai X; Mulla J; Cheng Z; Wands JR; Huang CK
    Dig Dis Sci; 2021 Apr; 66(4):1080-1089. PubMed ID: 32445050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
    Bai X; Zhang H; Zhou Y; Nagaoka K; Meng J; Ji C; Liu D; Dong X; Cao K; Mulla J; Cheng Z; Mueller W; Bay A; Hildebrand G; Lu S; Wallace J; Wands JR; Sun B; Huang CK
    Hepatology; 2021 May; 73(5):1747-1763. PubMed ID: 32740973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartate β-hydroxylase (ASPH) Accelerates Intrahepatic Cholangiocarcinoma Metastasis
    Zou Y; Lin J; Liu J; Zhang F; Yang T; Gong J; Jiang T; Zuo J; Song R; Shen H; Shen F; Li J
    Curr Protein Pept Sci; 2023; 24(5):436-446. PubMed ID: 37132101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage.
    Yu W; Xiang Y; Luo G; Zhao X; Xiao B; Cheng Y; Feng C; Duan C; Xia X; Wong VKW; Dai R
    Cancer Biother Radiopharm; 2018 Aug; 33(6):258-265. PubMed ID: 29957018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma.
    Shi Y; Cui X; Jiang T; Pan Y; Lin Y; Feng X; Ding Z; Yang C; Tan Y; Wang H; Dong L
    Cell Death Dis; 2022 Sep; 13(9):799. PubMed ID: 36123339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives.
    Gönül Geyik Ö; Anichini G; Ulukaya E; Marra F; Raggi C
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infigratinib for cholangiocarcinoma.
    Sadeghi S
    Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic parameters of human aspartate/asparagine-β-hydroxylase suggest that it has a possible function in oxygen sensing.
    Brewitz L; Tumber A; Schofield CJ
    J Biol Chem; 2020 Jun; 295(23):7826-7838. PubMed ID: 32107312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with aspartate-β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma.
    Noda T; Shimoda M; Ortiz V; Sirica AE; Wands JR
    Hepatology; 2012 Jan; 55(1):86-97. PubMed ID: 21898484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Treatment for Cholangiocarcinoma.
    Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S
    Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells.
    Gentilini A; Lori G; Caligiuri A; Raggi C; Di Maira G; Pastore M; Piombanti B; Lottini T; Arcangeli A; Madiai S; Navari N; Banales JM; Di Matteo S; Alvaro D; Duwe L; Andersen JB; Tubita A; Tusa I; Di Tommaso L; Campani C; Rovida E; Marra F
    Hepatology; 2021 Oct; 74(4):2007-2020. PubMed ID: 33959996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.